Recombinant factor Vlla reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 11, 2003, Pages 2368-2373

  Lisman, T ^a,b   Bljsterveld, N R ^c   Adelaaeijer, J ^a   Meijers, J C M ^a,b   Levi, M ^c   Nieuwenhuis, H K ^a   De Groot, P G ^a,b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fibrinolysis; Fondaparinux; rFVIIa; TAFI

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; FIBRINOLYTIC AGENT; FONDAPARINUX; POLYSACCHARIDE; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; BLOOD CLOTTING TEST; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; KINETICS; PHYSIOLOGY;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; FACTOR VII; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; POLYSACCHARIDES; RECOMBINANT PROTEINS;

EID: 4444277942     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00536.x     Document Type: Article

References (29)

1. Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, Zandberg P, van Amsterdam RGM, van Boeckel CAA, Meuleman DG. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
2. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. NEngl J Med 2001; 344: 619-25.
3. Lassen M.R Bauer KA, Eriksson BI, Turpie AG. Postoperative fonda parinux versus preoperative enoxaparin for prevention of venous throm- boembolism in elective hip-replacement surgery: a randomised double- blind comparison. Lancet 2002; 359: 1715-20.
4. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux com pared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
5. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboem bolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
6. The Rembrandt Investigators. Treatment of proximal deep vein throm bosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102: 2726-31.
7. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ. van de Werf for the PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
8. Vuillemenot A, Schiele F, Meneveau N, Claudel S, Donat F, Fontecave S, Cariou R, Samama MM, Bassand JP. Efficacy of a synthetic penta saccharide, a pure factor Xa inhibitor, as an antithrombotic agent - a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81: 214-20.
9. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complica tions of anticoagulant treatment. Chest 2001; 119: 108S-21S.
10. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: a Meta-analysis of 4 Randomized Double-blind Studies. Arch Intern Med 2002; 162: 1833-40.
11. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
12. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor Vila. Thromb Haemost 1999; 82: 531-9.
13. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S107-11.
14. Poon MC, d'Oiron R, Hann I, Negrier C, de Lumley L, Thomas A, Karafoulidou A, Demers C, Street A, Huth-Kuhne A, Petrini P, Fressi-naud E, Morfini M, Tengborn L, Marques-Verdier A, Musso R, Deve- cioglu O, Houston DS, Lethagen S, Van Geet C, von Depka M, Berger C, Beurrier P, Britton HA, Gerrits W, Guthner C, Kuhle S, Lorenzo JJ, Makris PE, Nohe N, Paugy P, Pautard B, Torchet MF, Trillot N, Vicariot M, Wilde J, Winter M, Chambost H, Ingerslev J, Peters M, Strauss G. Use of recombinant factor Vila (NovoSeven) in patients with Glanz- mann thrombasthenia. Semin Hematol 2001; 38: 21-5.
15. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J. Reduced transfusion requirements by recombinant factor Vila in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71: 402-5.
16. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor Vila. Lancet 1999; 354: 1879.
17. Friederich PW, Geerdink MGF, Spataro M, Messelink EJ, Henny ChP, Buller HR, Levi M. The effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) on perioperative bloodloss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coag Fibrinol 2000; 11: sl29-32.
18. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JCM, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor Vila in plasma from patients with severe haemo philia A. Blood 2002; 99: 175-9.
19. von dem Borne PA, Kr Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin- activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
20. Van Wijnen M, Stam JG, Chang GTG, Meijers JCM, Reitsma PH, Bertina RM, Bouma BN. Characterization of mini-protein S, a recom binant variant of protein S that lacks the sex hormone binding globulin- like domain. Biochem J 1998; 330: 389-96.
21. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phos- pholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-6.
22. Lisman T,Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, de Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
23. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
24. von dem Borne PA, Kr Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
25. Broze GJ Jr. Higuchi DA. Coagulation-dependent inhibition of fibri nolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
26. Eriksson BI, Lassen MR. Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery: a Multicenter, Randomized, Placebo-Controlled, Double-blind Study. Arch Intern Med 2003; 163: 1337-42.
27. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting acti vated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-62.
28. Lisman T, de Groot PG. Rebuttal to: Effect of heparin on TAFI- dependent inhibition of fibrinolysis. J Thromb Haemost 2003; 1: 200-1.
29. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile. Thromb Haemost 2001; p3094 [abstract]